Analysts’ recommendations and target price
Wall Street analysts expect a potential upside of 21.63% for Alexion Pharmaceuticals (ALXN) based on the stock’s closing price on March 21.
Analysts first revised the company’s target price downward from $163.06 in January to $161.48 in February and then raised it to $163.24 in March. The current consensus analyst recommendation for the stock is a “buy.”
Of the 18 analysts covering Alexion Pharmaceuticals, five have given it “strong buys,” ten have given it “buys,” and three have given it “holds.” The highest target price estimate for the company is $188, and the lowest is $125.
On March 21, Alexion Pharmaceuticals closed at $134.21, 1.94% higher than its previous closing price, 45.00% higher than its 52-week low of $92.56, and 4.66% lower than its 52-week high of $140.77. The company’s market cap is $29.497 billion.
Based on its closing price on March 21, Alexion Pharmaceuticals has reported returns of -0.50% in the last week, 3.37% in the last month, and 26.63% in the last quarter. The company has reported returns of 11.08% in the last half year, 11.64% in the last year, and 37.85% year-to-date.
Revenue and EPS estimates
In its fourth quarter, Alexion Pharmaceuticals reported revenue of $1.13 billion, a YoY (year-over-year) rise of 24.08% and $70.06 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $2.14, a YoY rise of 44.59% and $0.30 higher than the consensus estimate.
Analysts expect Alexion Pharmaceuticals’ revenue to see YoY rises of 21.05% to $1.13 billion in the first quarter, 12.24% to $1.17 billion in the second quarter, 18.09% to $1.21 billion in the third quarter, and 10.65% to $1.25 billion in the fourth quarter of 2019. Analysts also expect Alexion’s non-GAAP EPS to see YoY rises of 30.04% to $2.18 in the first quarter, 10.88% to $2.30 in the second quarter, 18.11% to $2.39 in the third quarter, and 12.23% to $2.40 in the fourth quarter.
Analysts expect Alexion Pharmaceuticals’ revenue to see YoY rises of 14.93% to $4.75 billion in 2019, 13.11% to $5.37 billion in 2020, and 7.11% to $5.75 billion in 2021. They expect its non-GAAP EPS to see YoY rises of 17.27% to $9.29 in 2019, 12.98% to $10.49 in 2020, and 9.77% to $11.52 in 2021.
Next, we’ll discuss analysts’ recommendations and projections for Vertex Pharmaceuticals.